Recro Pharma, Inc. (NASDAQ: REPH) is a revenue-generating specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute post operative pain. Recro Pharma has two product candidates in mid- to late-stage clinical trials for the management of acute postoperative pain. IV/IM meloxicam, a proprietary, long-acting preferential COX-2 inhibitor has successfully completed multiple Phase 2 clinical trials and is ready to begin pivotal phase 3 clinical trials. Dex-IN, a proprietary intranasal formulation of dexmedetomidine, is currently being tested in phase 2 clinical trials. For more information, visit the company’s website at www.recropharma.com